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ABSTRACT	 	Longitudinal	Extensive	Transverse	Myelitis	(LETM)		characterized	by	spinal	cord	inflammation	extending	vertically	through	three	or	more	vertebral	segments.	Early	serological	testing	for	NMO-IgG	antibodies	in	suspected	 LETM	 is	 important	 for	 prompt	 diagnosis,	 indicating	 prognosis	 and	 establishing	 appropriate	therapy	to	reduce	the	risk	of	future	relapses	or	disease	progression.	This	is	a	case	of		35-year-old	female	complaining	of	weakness	of	both	lower	limbs,	bladder	and	bowel	disturbances	with	curdle	like	sensation,	loss	of	sensation.	MRI	C	and	D	spine	plain	and	contrast	showed	T2	hyperintensity	in	spinal	from	C4	to	D7	s/o	of	demyelination,	thinning	of	spinal	cord	noted	at	upper	dorsal	level.	Anti	nuclear	antibody	ELISA	test	revealed	 positive	 indicating	 the	 presence	 of	 NMO	 IgG	 antibodies.	 Due	 to	 poor	 prognosis	 of	 the	 disease	patient	was	advised	to	be	in	observation	for	15	days	and	planned	for	2	doses	of	cyclophosphamide	750	mg.	Mean	while	symptomatic	treatment	was	also	given.	Performing	NMO	antibodies	test	as	early	as	possible	in	the	case	of	symptomatic	assessment	of	either	LETM	or	Multiple	sclerosis,	which	 facilitates	 the	choice	of	treatment	for	better	patient	care	and	enhanced	health	related	quality	of	life.	
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INTRODUCTION		Neuromyelitis	optica	spectrum	disorders	(NMOSD)or	Neuro	myelitis	optica	(NMO)	are	inflammatory	disor-ders	of	central	nervous	system	characterized	by	se-vere,	 immune	 mediated	 demyelination	 and	 axonal	damage	 predominantly	 targeting	 optic	 nerves	 and	spinal	cord.[1]	NMOSD	include	either	Longitudinal	Ex-tensive	Transverse	Myelitis	(LETM)	or	Optic	neuritis.	
LETM	 is	 characterized	 by	 spinal	 cord	 inflammation	extending	vertically	through	three	or	more	vertebral	segments.	It	may	occur	as	an	uncommon	manifesta-tion	 of	 SLE	 or	 other	 autoimmune	 diseases[2].	 Signs	and	 symptoms	 include	 neurological	 dysfunction	 in	motor	and	sensory	tracts	on	both	sides	of	spinal	cord.	Involvement	of	motor	and	sensory	control	pathways	frequently	produce	altered	sensation,	Weakness,	Uri-nary	or	bowel	dysfunction[3].			Early	 serological	 testing	 for	NMO-IgG	antibodies	 in	suspected	LETM	 is	 important	 for	prompt	diagnosis,	indicating	 prognosis	 and	 establishing	 appropriate	therapy	to	reduce	the	risk	of	 future	relapses	or	dis-ease	progression.	Patients	with	NMO-IgG	seropositiv-ity	are	considered	at	increased	risk	of	future	relapses	and	 development	 of	 whole	 NMO	 disease	 spectrum.	Other	diagnostic	tests	include	MRI	spine,	Neurophys-iological	tests.	[4]	
Table 1: NMO-Antibody test NMO-NMOSD-SERUM	Neuro	myelitis	optica	IgG	antibodies	STRONGLY	POSITIVE	Anti-myelin	oligodendrocyte	glycoprotein	(MOG)		IgG	antibodies	NEGATIVE		
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The	goal	of	treating	acute	events	is	to	improve	relapse	symptoms	and	restore	neurological	function[5].	Yana-gawa	et	al.	reported	that	early	detection	of	NMO-IgG	combined	with	proper	immunotherapy	represents	a	key	 to	a	good,	 long	 term	prognosis[6].	The	 rationale	for	treatment	of	acute	and	recurrent	attacks	is	based	upon	evidence	that	humoral	immunity	plays	a	role	in	pathogenesis	 of	 NMOSD.	 Intial	 treatment	with	 high	dose	 intravenous	 methylprednisolone	 1g	 daily	 for		three	to	five	consecutive	days.	For	patients	with	se-vere	 symptoms,	 unresponsive	 to	 glucocorticoids,	Therapeutic	plasma	exchange	is	the	suggested	rescue	treatment.	 Patients	with	 severe	 attacks	 do	 better	 if	plasma	exchange	is	started	early	as	adjunctive	ther-apy	with	glucocorticoids.	If	both	immunotherapy	and	plasma	 exchange	 do	 not	 improve	 symptoms,	 treat-ment	with	intravenous	immunoglobulins	or	an	esca-lation	to	cytoablative	therapy	such	as	cyclophospha-mide	may	be	considered.	[5]	
CASE	STUDY	We	present	the	case	of	a	35-year-old	female	(K/C/O	paraparesis	 2016	 recovered)	 complaining	 of	weak-ness	of	both	lower	limbs,	bladder	and	bowel	disturb-ances	with	curdle	like	sensation,	loss	of	sensation	be-low	chest	area	since	2	months.	Patient	also	presented	with	 history	 of	 chronic	 backache	 from	 2	 years,	 2	months	back	 she	developed	paresthesias	 ascending	type	 in	both	 lower	 limbs	within	3	days	up	 to	 chest	area,	unable	to	walk	or	move	around	in	bed.	On	exam-ination	patients	blood	pressure	was	130/90	mm	of	Hg,	pulse	rate	was	70	bpm,	power	of	upper	limbs	4/5,	lower	limbs	1/5.	Gait	could	not	be	tested.	Serum	 electrolytes,	 Renal	 function	 tests	 and	 liver	function	tests	were	found	to	be	normal.	MRI	C	and	D	spine	plain	and	contrast	showed	T2	hyper	intensity	in	spinal	from	C4	to	D7	s/o	of	demyelination,	thinning	of	spinal	cord	noted	at	upper	dorsal	level.	Anti-nuclear	antibody	ELISA	test	revealed	positive	indicating	the	presence	of	antibodies.	
Serum	analysis	 for	 the	presence	of	NMO	antibodies	showed	in	(Table 1)	Patient	 found	to	have	elevated	 levels	of	plasma	 lac-tate-53mg/dl	 (4.50-19.80).	With	 the	evidence	of	 la-boratory	investigations,	patient	was	diagnosed	with	“NMO	 antibodies	 associated	 longitudinal	 extensive	transverse	myelitis”.	 Treatment	 include	 patient	 ini-tially	treated	with	1g	of	intravenous	methylpredniso-nolone,	no	significant	improvement	in	the	patient.	5	cycles	of	plasmapheresis,	also	known	as	plasma	ex-change	 (PLEX)	 were	 done,	 which	 is	 often	 recom-mended	for	moderate	to	severe	forms	of	LETM.	Due	to	poor	prognosis	of	the	disease	patient	was	advised	to	be	 in	 observation	 for	15	days	 and	planned	 for	2	doses	 of	 cyclophosphamide	 750	 mg.	 Meanwhile	symptomatic	treatment	was	also	given.	After	giving	2	doses	of	cyclophosphamide	750	mg.	Pa-tient	was	stabilized	and	symptoms	were	relieved.so	patient	was	 discharged	with	 the	medications:Gaba-pin	NT		400/10	twice	daily,	pantoprazole	40	mg	once	daily	 before	 breakfast,	 calcium	 and	 multivitamin	twice	 daily	 and	 monthly	 cyclophosphamide	 during	follow	up	to	reduce	the	number	of	relapses.	
DISCUSSION	LETM	is	an	inflammatory	condition	of	the	spinal	cord	causing	variable	levels	of	morbidity	and	mortality[4].	Traditionally	 the	 majority	 of	 LETM	 cases	 were	thought	to	be	characterized	by	perivascular	infiltra-tion	by	monocytes	and	lymphocytes	in	the	spinal	cord	lesion.	 To	distinguish	LETM	 from	multiple	 sclerosis	and	to	provide	appropriate	 therapy	we	additionally	emphasize	the	clinical	importance	of	NMO-IgG	sero-logical	 status.	A	previous	 report	has	 suggested	 that	NMO–IgG	 antibodies	 are	 present	 in	 approximately	38%	of	LETM	patients	following	an	initial	attack	and	is	 associated	with	greater	 than	60%	risk	of	 relapse	within	1	year	and	development	of	optic	neuritis[7].	En-couragingly,	LETM	is	often	responsive	to	acute	immu-notherapy	with	steroids,	plasma	exchange[8].	We	ob-served	that	in	this	case	the	patient	was	not	responded	
Table 2: Complete blood count 
Lab Parameter Observed Value Normal Value 
Haemoglobin 11.5g/dl 12-16g/dl 
Red blood cells 4.03mill./cumm 4.5-5mill./cumm 
White blood cells 11900cells/cumm 4000-11000cells/cumm 
Platelets 1.68 L/cumm 1.5-4 L/cumm 
Erythrocyte sedimentation rate 14 mm/1st Hr 20-40mm/1st Hr 
Table 3: Pharmacological treatment provided 
S.no Dosage form Medications Dose Route Frequency 
1 Tablet Gabapentin + Nortryptylline 100mg Oral TID 
2 Tablet Shelcal (calcium) 500mg Oral OD 
3 Injection Pantoprazole 40mg Intravenous TID 
4 Injection Methyl prednisones 1g Intravenous OD 
5 Injection Cefoperazone + Sulbactum 1.5g Intravenous BD 
6 Capsule Vitamin D 60,000u Oral Weekly once 
7 Injection Cyclophosphamide 750mg Intravenous Monthly once 
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well	to	the	steroid	therapy	and	plasmaphresis,	so	an	alkylating	agent	such	as	cyclophosphamide	was	con-sidered.	
CONCLUSION	LETM	can	be	specifically	diagnosed	with	the	help	of	NMO-IgG	antibodies	test,	so	that	we	can	differentiate	LETM	with	Multiple	sclerosis	in	initial	stages.	We	sug-gest	to	perform	NMO	antibodies	test	as	early	as	pos-sible	in	the	case	of	symptomatic	assessment	of	either	LETM	 or	 Multiple	 sclerosis,	 which	 facilitates	 the	choice	of	treatment	for	the	better	patient	care	and	en-hanced	health	related	quality	of	life.	Further	studies	with	 larger	 cohort	 should	be	needed	 to	 consolidate	the	 findings	 and	 it	 potentially	 leads	 to	 therapeutic	recommendations	 in	majority	of	 the	NMO-IgG	sero-positive	patients.	
ABBREVATIONS	NMOSD:	 Neuromyelitis	 optica	 spectrum	 disorders,	LETM:	 Longitudinal	 extensive	 transverse	 myelitis,	PLEX:	Plasma	exchange.	
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